The Valley Desk

NCT05746559 · Interventional trial

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Overall registry status Terminated

Phase 3

Conditions CKD, Cardiac Disease, Cardiopulmonary Bypass, Chronic Kidney Disease

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov